Oculis Management Engages Investors This September
Oculis Holding AG (NASDAQ: OCS / XICE: OCS), a pioneering biopharmaceutical player dedicated to developing advanced treatments for eye-related and neuro-ophthalmic disorders, has exciting news for investors. The management team has confirmed their participation in several influential investor conferences throughout September. These events are crucial for keeping stakeholders informed and engaged with the company's innovative pipeline aimed at addressing significant medical needs.
Key Conferences Announced
Wells Fargo Healthcare Conference
The company will be present at the Wells Fargo Healthcare Conference from September 3 to 5 in Boston. Riad Sherif, M.D., the Chief Executive Officer, alongside Sylvia Cheung, Chief Financial Officer, will represent Oculis at this prominent event, discussing their strategic vision and future prospects.
H.C. Wainwright 27th Annual Global Investment Conference
Following the Wells Fargo event, Oculis is set to participate in the H.C. Wainwright 27th Annual Global Investment Conference. The conference takes place from September 8 to 10 in New York, where a fireside chat with Riad Sherif, M.D., is scheduled for September 8 at 2:30 PM ET. Investors interested in this session will have a chance to gain deeper insights into Oculis’ initiatives and developments.
Continuing Engagement with Investors
Baird Global Healthcare Conference
On September 9 and 10, Oculis will attend the Baird Global Healthcare Conference also in New York. During this time, an update session led by Riad Sherif is arranged for September 9 at 3:45 PM ET, where attendees can look forward to hearing about recent advancements in the company's clinical pipeline.
Pareto Securities 16th Annual Healthcare Conference
Moreover, on September 16, Oculis will present at the Pareto Securities 16th Annual Healthcare Conference in Stockholm. Páll Ragnar Jóhannesson, Chief Business Officer, will provide additional updates on the company’s progress at this event.
Leerink Partners Biopharma Summit
Lastly, from September 17 to 19, Oculis is participating in the Leerink Partners Biopharma Summit in Healdsburg, where CEO Riad Sherif will once again be on hand, continuing to engage with investors about the company’s innovative efforts.
Opportunities for One-on-One Meetings
Throughout these conferences, Oculis invites interested investors to schedule one-on-one meetings. This is an excellent opportunity for stakeholders to connect directly with the management team, allowing for personalized discussions about future strategies and the ongoing research that drives Oculis' mission.
For more information regarding the company’s webcast links and conference details, stakeholders can find updates on Oculis’ website. These links will be available on their dedicated Events and Presentation page within the Investors & Media section.
About Oculis
Oculis is renowned for its commitment to revolutionizing the treatment landscape for ophthalmic and neuro-ophthalmic conditions. The company’s late-stage clinical pipeline is robust, featuring significant candidates like OCS-01, which is in pivotal registration studies aimed at offering a non-invasive solution for diabetic macular edema. Additionally, OCS-05 is a promising neuroprotective therapy concerning acute optic neuritis, while OCS-02 exemplifies innovation in personalized medicine for dry eye disease. Set against a backdrop of leadership experienced in biopharmaceutical development and bolstered by global investor confidence, Oculis is positioned for impactful growth.
Frequently Asked Questions
What is Oculis Holding AG?
Oculis Holding AG is a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases.
Where will Oculis be presenting in September?
Oculis will be present at various conferences, including Wells Fargo, H.C. Wainwright, Baird Global, Pareto Securities, and Leerink Partners events.
Who from Oculis will be attending these conferences?
Key executives including Riad Sherif, M.D., and Sylvia Cheung will participate, presenting updates and engaging with investors.
How can investors schedule meetings with Oculis representatives?
Investors should contact their representatives at the sponsoring institutions to request one-on-one meetings during the conferences.
What are the main projects under development at Oculis?
Oculis' main projects include OCS-01, OCS-05, and OCS-02, which target significant unmet medical needs in ocular health.
